15 Quotes by Henry Scott

This approval takes some risk out of the equation for them. If they can get the production capacity, it has the potential to be a significant drug. The big issue for Bristol is patent expirations and whether the pipeline can offset them.

A big wildcard is how much capacity do these guys have.

It's the best possible win for the case, but it is not the end of the battle. The next test case will really be long-term users. Investor sentiment certainly swings probably more than it should on each individual case.

It was mediocre. I thought we'd see more, but they flew fairly well. We'll get on a better field this afternoon.

I still believe Pfizer will win the U.S. case, but you can never make any assumptions in a patent dispute.

Investors will look at the quarter and like fact that they beat estimates.